Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Funding support
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research ArticleAutoimmunityImmunology Open Access | 10.1172/JCI196325

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Ho-Chung Chen,1 Madison F. Bang,1 Hsing-Hui Wang,2 Karl B. Shpargel,3 Lisa A. Kohn,4 David Sailer,2 Shile Zhang,5 Ethan C. McCarthy,1 Maryamsadat Seyedsadr,1 Satchel Stevens,1 Caitlyn L.H. Pham,1 Zikang Zhou,1 Xihui Yin,6 Nicole M. Wilkinson,1,7 Esther M. Peluso,5,7 Christian Bustillos,1 Jessica G. Ortega,4 Lixin Yang,3 Ashlyn A. Buzzelli,3 Reina C. Capati,8 Dennis J. Chia,8 Steven D. Mittelman,8 Christina M. Reh,8 Jason K. Whitmire,3 Melissa G. Lechner,4 Willy Hugo,4 and Maureen A. Su1,8

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Chen, H. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Bang, M. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Wang, H. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Shpargel, K. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Kohn, L. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Sailer, D. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Zhang, S. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by McCarthy, E. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Seyedsadr, M. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Stevens, S. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Pham, C. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Zhou, Z. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Yin, X. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Wilkinson, N. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Peluso, E. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Bustillos, C. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Ortega, J. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Yang, L. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Buzzelli, A. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Capati, R. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Chia, D. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Mittelman, S. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Reh, C. in: PubMed | Google Scholar

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Whitmire, J. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Lechner, M. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Hugo, W. in: PubMed | Google Scholar |

1Department of Microbiology, Immunology, and Molecular Genetics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

2Department of Pediatrics and

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

4Department of Medicine and

5Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

6Department of Biology, Massachusetts Institute of Technology, Boston, Massachusetts, USA.

7UCLA/California Institute of Technology Medical Scientist Training Program and

8Department of Pediatrics, UCLA David Geffen School of Medicine, Los Angeles, California, USA.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Find articles by Su, M. in: PubMed | Google Scholar |

Published December 16, 2025 - More info

Published in Volume 136, Issue 4 on February 16, 2026
J Clin Invest. 2026;136(4):e196325. https://doi.org/10.1172/JCI196325.
© 2026 Chen et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published December 16, 2025 - Version history
Received: June 3, 2025; Accepted: December 10, 2025
View PDF
Abstract

Type 1 diabetes mellitus (T1D) is a chronic disease caused by an unremitting autoimmune attack on pancreatic β cells. This autoimmune chronicity is mediated by stem-like progenitor CD8+ T cells that continually repopulate the pool of β cell–specific cytolytic effectors. Factors governing the conversion of progenitors to effectors, however, remain unclear. T1D has been linked to a chromosomal region (Xp13-p11) that contains the epigenetic regulator UTX, which suggests a key role for UTX in T1D pathogenesis. Here, we show that T cell–specific UTX deletion in NOD mice protects against T1D development. In T cells of NOD mice and patients with T1D, UTX ablation resulted in the accumulation of CD8+ progenitor cells with a concomitant decrease of effector cells, suggesting a key role for UTX in poising progenitors for transition to effectors. Mechanistically, UTX’s role in T1D was independent of its inherent histone demethylase activity but instead relied on binding with transcription factors (TCF1 and STAT3) to coregulate genes important in the maintenance and differentiation of progenitor CD8+ T cells. Together, these findings identify a critical role for UTX in T1D and the UTX:TCF1:STAT3 complex as a therapeutic target for terminating the long-lived autoimmune response.

Graphical Abstract
graphical abstract
Introduction

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease in which insulin-producing β cells are destroyed by a sustained T cell attack (1). As a consequence, clinical symptoms do not remit, and patients require lifelong exogenous insulin administration. This contrasts with Guillain-Barré syndrome, acute disseminated encephalomyelitis, and other self-limited autoimmune conditions, in which the immune response wanes and clinical symptoms usually resolve within months. What underlies autoimmune persistence in T1D is not completely understood, and identifying mechanisms that perpetuate chronic immune-mediated destruction is an important step toward developing therapeutic approaches that interrupt this process.

Much has been learned about the mechanisms of immune chronicity through studies in models of chronic virus infection and progressive cancer. Similar to the T1D autoimmune response, the immune responses in chronic virus infection and progressive cancer are characterized by continued T cell activation by persistent antigens and a prominent, long-lived CD8+ T cell stem-like progenitor (Tprog) population (2–4). In all 3 scenarios, these Tprog cells sustain persistent immune responses by continually replenishing the pool of terminally differentiated CD8+ T cells. In chronic virus infection and progressive cancers, Tprog cells give rise to CD8+ T cell effector populations that become exhausted and fail to eradicate the immune threat (5, 6). In T1D, on the other hand, these short-lived, terminally differentiated CD8+ T mediator cells (Tmed) retain their cytolytic function and aggressively destroy β cells (3). Thus, a critical feature of T1D pathogenesis is the persistent conversion of long-lived CD8+ Tprog cells to Tmed cells with effector function.

Through genetic linkage studies, T1D has been associated with gene loci with key roles in Tprog cells. For instance, T1D has been associated with polymorphisms in the gene encoding TCF1 (7, 8), a transcription factor (TF) critical in Tprog cell formation, maintenance, and function (9). Additionally, accelerated T1D in mice and humans has been linked with gain-of-function mutations in STAT3 (10), a TF implicated in the conversion of Tprog to effector cells (11). Remarkably, T1D acceleration in STAT3 gain-of-function mice has been attributed to increased CD8+ T cell effectors (10, 12), a finding in line with STAT3’s role in CD8+ Tprog to effector cell conversion (11). Together, these findings highlight the importance of genetic regulators of Tprog cells in the T1D autoimmune response.

T1D has also been linked to a region of chromosome X (Xp13-p11) that contains the epigenetic regulator UTX (ubiquitously transcribed tetratricopeptide repeat, X chromosome; encoded by KDM6A) (13). UTX has pleiotropic functions, including intrinsic histone demethylase activity (14, 15). However, whether UTX plays a role in T1D and the cellular and molecular mechanisms by which UTX may function remain unclear (13). Here, we show that T cell–specific UTX expression was required for T1D through its role in driving stem-like Tprog cells to become cytolytic Tmed cells. This role was independent of its demethylase function but instead involved cooperative interactions between UTX and the TFs TCF1 and STAT3. UTX, TCF1, and STAT3 co-occupancy at key progenitor and effector gene loci enforces a transcriptional program that drives Tprog to effector cell conversion. These findings point to UTX as a critical regulator of the T1D autoimmune response and point to targeting UTX:TCF1:STAT3 mechanisms as a potential approach for interrupting the persistent autoimmune attack.

Results

UTX in T cells of NOD mice is required for T1D and alters CD8+ T cell subset distribution. UTX has been implicated in controlling T cell differentiation in anticancer and antiviral immunity (16–18), but its role in diabetogenic T cell responses is unknown. Given genetic data linking a UTX-containing chromosomal region and T1D, we hypothesized that UTX may play a key role in T cell–mediated T1D pathogenesis. To test this, we generated NOD mice with T cell–specific UTX deletion (UTXfl/fl Lck-Cre+, herein referred to as NOD-UTXTCD mice). As expected, UTX protein was decreased in T cells isolated from NOD-UTXTCD mice, compared with UTX-sufficient littermate controls (UTXfl/fl Lck-Cre-; herein referred to as NOD-WT mice) (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI196325DS1). By 30 weeks of age, none of the NOD-UTXTCD female mice developed diabetes, in contrast to almost 80% of NOD-WT female littermate controls (Figure 1A). H&E-stained pancreas sections showed significantly reduced immune infiltration in the islets of NOD-UTXTCD mice, compared with NOD-WT controls (Figure 1, B and C). Notably, this protection from diabetes is independent of UTX’s intrinsic histone demethylase activity, since NOD mice with point mutations in UTX’s demethylase domain (NOD-UTXDemethylase-dead or NOD-UTXDMD mice) continue to develop diabetes at the same rate as NOD.WT controls (Supplemental Figure 1B). Thus, T cell–specific UTX deficiency protects against diabetes and insulitis in NOD mice in a demethylase-independent manner.

Resistance to T1D in NOD-UTXTCD mice is associated with altered distributioFigure 1

Resistance to T1D in NOD-UTXTCD mice is associated with altered distribution of pLN CD8+ T cells. (A) Diabetes-free incidence curves of NOD-UTXTCD vs. NOD-WT female littermates. ****P < 0.0001; log rank test. (B and C) Representative H&E-stained pancreas sections (B) and cumulative islet infiltration scores (C) from NOD-UTXTCD vs. NOD-WT female littermates. *P < 0.05; Tukey’s multiple comparisons test. Scale bar: 200 μm. (D) Scheme for 10X Genomics single-cell RNA sequencing (scRNA-seq) of CD45+ cells from pLNs of NOD-WT and NOD-UTXTCD mice. (E and F) UMAP of CD45+ cells (E) and subclustered CD8+ T cells (F). (G) Gene expression across the CD8+ T cell clusters. (H) Comparison of subset frequencies of CD8+ Tprog-like and CD8+ Tmed-like populations. CD8+ Tprog-like, *P = 0.015; CD8+ Tmed-like, **P = 0.026; 2-sided, unpaired Mann-Whitney test.

We next sought to explore the cellular mechanism by which UTX functions in T cells to promote T1D. Prior to infiltrating pancreatic islets, diabetogenic T cells are first primed in the pancreatic lymph nodes (pLNs) (3, 19). To delineate how UTX deficiency alters pLN T cell dynamics in NOD mice, we performed single-cell RNA-seq (scRNA-seq) of pLN immune cells (CD45+) from 8- and 13-week-old NOD-WT and NOD-UTXTCD mice (Figure 1D; n = 6 per genotype). These ages represent distinct stages in T1D autoimmunity development: 8 weeks represents a stage when immune cell infiltration is prominent in islets, and 13 weeks represents a stage immediately prior to overt diabetes (20). UMAP clustering of 97,400 cells showed 7 major immune cell populations, including CD8+ T cells, CD4+ T cells, B cells, and myeloid cells (Figure 1E and Supplemental Data File 1). Frequencies of these populations were similar between NOD-WT and NOD-UTXTCD mice (Supplemental Figure 1, C and D). We further evaluated CD4+ and CD8+ T cell populations to assess for primary alterations resulting from T cell–specific UTX deficiency.

Subclustering of CD4+ T cells yielded 10 populations (Supplemental Figure 2A), including T follicular helper (Tfh) and Tregs. Frequencies of key autoimmunity-associated CD4+ T cell subsets in the pLN were similar between NOD-WT and NOD-UTXTCD mice (Supplemental Figure 2B). Moreover, flow cytometric analysis of pLNs showed similar frequencies of CD4+ T cell subsets (Tfh [CXCR5+ PD1+], Th1 [T-bet+], and Treg [Foxp3+]) (Supplemental Figure 2C) and proinflammatory cytokine-producing CD4+ cells (Supplemental Figure 2D) between NOD-WT and NOD-UTXTCD mice. Thus, pLN CD4+ T cell distribution was largely unchanged by T cell–specific UTX deficiency in NOD mice.

In contrast, substantial changes were noted in the distribution of CD8+ T cell subsets between NOD-WT and NOD-UTXTCD mice. CD8+ T cells were subclustered into 8 populations (Figure 1F), which included a “CD8+ Tprog-like” population that expressed genes associated with stem-like progenitor cells (Tcf7 [which encodes TCF1], Slamf6 [which encodes Ly108], Sell, Myb, Ikzf2, Id3) (Figure 1G and Supplemental Figure 3A) and a “CD8+ Tmed-like” effector population that expressed genes associated with terminally differentiated autoimmune mediators (Nkg7, Cxcr6, Thy1) (3, 9) (Figure 1G). Strikingly, a higher frequency of CD8+ Tprog-like and a lower frequency of CD8+ Tmed-like, cells were seen in the pLNs of NOD-UTXTCD mice, compared with NOD-WT littermates (Figure 1H and Supplemental Figure 3, B and C). Thus, protection from T1D in NOD-UTXTCD mice is associated with an altered distribution of pLN CD8+ T cell subsets expressing markers of stem-like progenitors and effectors.

UTX in T cells promotes CD8+ T cell transition from progenitor to cytolytic effector state in T1D. Within the pLNs of NOD mice, stem-like progenitors (Tprog) have been reported to differentiate into terminally differentiated autoimmune mediators (Tmed), which then enter the pancreatic islets to destroy β cells (3). In line with this report, pseudotime trajectory analysis of our scRNA-seq dataset suggested a differentiation pathway that starts with the CD8+ Tprog-like population, moves through an intermediate population (CD8+ T intermediate), and ends in the CD8+ Tmed-like population (Figure 2A). Along the pseudotime axis, expression of stem-like progenitor-associated genes (Tcf7, Slamf6) was highest in CD8+ Tprog-like cells, decreased in the CD8+ T intermediate cells, and lowest in CD8+ Tmed-like cells (Figure 2, B and C). On the other hand, expression of effector-associated genes (Thy1, Cxcr6) was lowest in the CD8+ Tprog-like cells and increased in CD8+ T intermediates and CD8+ Tmed-like cells (Figure 2, B and C). Of note, T cell–specific UTX deficiency altered this differentiation trajectory. Comparison of cell densities along the pseudotime trajectory revealed relative accumulation of NOD-UTXTCD CD8+ Tprog-like cells, compared with NOD-WT cells (Figure 2D). This difference was accompanied by a relative decrease in NOD-UTXTCD CD8+ Tmed-like cells, compared with NOD-WT cells. Together, these data suggest a potential block in the conversion of CD8+ Tprog to Tmed cells in NOD-UTXTCD mice.

Impaired conversion of stem-like progenitors to effectors in NOD-UTXTCD micFigure 2

Impaired conversion of stem-like progenitors to effectors in NOD-UTXTCD mice. (A) UMAP plot of CD8+ Tprog-like, CD8+ T intermediate, and CD8+ Tmed-like clusters (left), with cells color-coded along Slingshot pseudotime (right). (B) Heatmap of scRNA-seq expression for key genes, plotted along Slingshot pseudotime. (C) Expression of key genes along Slingshot pseudotime trajectory, color coded by clusters shown in UMAP (A, left). (D) Comparison of cell densities of CD8+ Tprog-like, CD8+ T intermediate, and CD8+ Tmed-like cells derived from 8-week-old NOD-WT (WT) vs. NOD-UTXTCD (UTXTCD) mice, plotted along Slingshot pseudotime trajectory. P < 2.2 e-16; asymptotic 2-sample Kolmogorov-Smirnov test. (E) Gating scheme for identifying Tprog-like and Tmed-like cells by flow cytometric analysis. (F) Representative flow cytometric plot (left) and average frequencies (right) of pLN Tprog-like (Ly108+CXCR6–) and Tmed-like (Ly108–CXCR6+) cells of NOD-WT and NOD-UTXTCD female littermates (15–29 weeks of age). ****P < 0.0001; ***P < 0.001; Student’s t test. (G) Working model: UTX promotes conversion of long-lived stem-like CD8+ T cell progenitors (Tprog) to short-lived mediators (Tmed), which then enter pancreatic islets to mediate β cell destruction.

To verify this finding, we turned to flow cytometric analysis, using previously reported cell surface markers to identify Tprog-like and Tmed-like cells (4). In this approach, reciprocal expression of Ly108 (Slamf6) and CXCR6 were used to distinguish Tprog-like (Ly108+CXCR6–) and Tmed-like (Ly108–CXCR6+) populations (Figure 2E). Supporting the validity of this gating strategy, expression of the stem-like TF TCF1 was higher in Ly108+CXCR6– Tprog-like populations than that in Ly108– CXCR6+ Tmed-like populations (Supplemental Figure 4A). Furthermore, expression of the CD39 mediator marker was lower in Ly108+CXCR6– Tprog-like cells than Ly108– CXCR6+ Tmed-like populations (Supplemental Figure 4B). Using this gating strategy, a significant increase in Tprog-like cells was seen in pLNs of NOD-UTXTCD mice, compared with NOD-WT (Figure 2F). At the same time, a significant decrease in Tmed-like populations was seen in pLNs of NOD-UTXTCD mice, compared with NOD-WT mice. Taken together, our scRNA-seq and flow cytometric analyses support a model in which UTX promotes conversion of CD8+ T cell progenitors to effectors, which then enter the pancreatic islets to destroy β cells and incite diabetes (Figure 2G). In support of the importance of UTX in diabetogenic CD8+ T cells, diabetes development was delayed in immunodeficient hosts after adoptive transfer with UTX-deficient CD8+ T cells, compared with UTX-sufficient (WT) CD8+ T cells (Supplemental Figure 4C).

UTX controls progenitor to cytolytic effector differentiation in β cell–specific CD8+ T cells. CD8+ T cells recognizing the pancreatic β cell antigen islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) are a major pathogenic population in mice and humans with T1D (21, 22). Remarkably, Gearty et al. reported that IGRP-specific stem-like progenitors (Tprog; Ly108+CD39–) give rise to both Tprog and autoimmune mediator (Tmed; Ly108–CD39+) populations, and as few as 20 pLN Tprog cells from NOD donors can induce diabetes in immunodeficient hosts (3). Given their potent diabetes-inducing potential, we sought to define the role of UTX in controlling the differentiation of IGRP-specific Tprog cells into cytolytic Tmed cells.

In keeping with the markers used by Gearty et al., we identified pLN CD8+ Tprog cells as Ly108+CD39– cells and Tmed cells as Ly108–CD39+ cells (3) (Figure 3A). As expected, Ly108+CD39– Tprog cells expressed higher levels of the progenitor marker TCF1 (Supplemental Figure 4D) and lower levels of the mediator marker CXCR6 than Ly108–CD39+ Tmed cells (Figure 3B). We further identified IGRP-specific T cells by their expression of CD44, a marker of antigen-experienced T cells, and their binding to tetramers containing the IGRP mimotope NRP-V7 (CD44+ NRP-V7+) (23). Using this gating approach, the frequency of Tprog cells among IGRP-specific, antigen-experienced CD8+ T cells (Ly108+CD39– cells within CD8+CD44+NRP-V7+) was increased in NOD-UTXTCD pLNs compared with that in NOD-WT pLNs (Figure 3C). At the same time, the frequency of Tmed (Ly108–CD39+) cells within antigen-experienced, IGRP-specific (CD8+CD44+NRP-V7+) cells was significantly lower in NOD-UTXTCD pLNs, compared with that in NOD-WT pLNs (Figure 3C). Similar findings were seen when CXCR6, rather than CD39, was used as a mediator marker (Supplemental Figure 4E). With age, the frequency of IGRP-specific Tmed (Ly108–CD39+ cells within CD8+CD44+NRP-V7+) cells increased in NOD-WT pLNs, while IGRP-specific Tprog (Ly108+CD39– cells within CD8+CD44+NRP-V7+) cells accumulated in NOD-UTXTCD pLNs (Supplemental Figure 4F). Together, these findings demonstrate a role for UTX in promoting the conversion of β cell–specific Tprog cells to Tmed cells in the pLN.

UTX promotes Tprog to Tmed conversion of β cell–specific CD8+ T cells.Figure 3

UTX promotes Tprog to Tmed conversion of β cell–specific CD8+ T cells. (A) Gating scheme for identifying Tprog and Tmed cells by flow cytometric analysis. (B) Representative histogram of CXCR6 expression in Tprog vs. Tmed cell populations identified by Ly108 and CD39 expression. (C) Representative flow cytometric plot (left), and average frequencies (right) of Tprog (Ly108+ CD39–) and Tmed (Ly108– CD39+) cells within antigen-experienced, IGRP-specific pLN CD8+ T cells (CD8+ CD44+ NRP-V7+) of NOD-WT and NOD-UTXTCD female littermates (15–29 weeks of age). ****P < 0.0001; ***P < 0.001; Student’s t test. (D) Scheme for adoptive transfer of pLN Tprog cells (Ly108+CD39–) from NOD-TCR 8.3 WT vs. NOD-TCR 8.3 UTXTCD mice into NOD.SCID recipients. (E) Representative flow cytometric plot (left) and average frequencies (right) of Tprog (Ly108+CD39–) or Tmed (Ly108–CD39+) among pLN antigen-experienced (CD8+CD44+) cells in hosts after adoptive transfer, as shown in D. Data from 2 replicate experiments are shown. **P < 0.01; *P < 0.05; Student’s t test.

To further delineate UTX’s functions within β cell–specific Tprog cells, we performed adoptive transfers of IGRP-specific Tprog cells into immunodeficient NOD.SCID recipients (Figure 3D). To isolate sufficient numbers of IGRP-specific Tprog cells for transfer, we exploited an NOD T cell receptor (TCR) transgenic mouse line (NOD-TCR 8.3) in which T cells express a TCR recognizing the IGRP206–214 epitope in the context of MHC class I (24). IGRP-specific CD8+ T cell progenitors (Ly108+CD39–) were sorted from 6-week-old NOD-TCR 8.3 mice with or without T cell–specific deficiency in UTX (NOD-TCR 8.3 UTXTCD or NOD-TCR 8.3 WT, respectively). Three weeks after transfer, an increased frequency of pLN Tprog cells (Ly108+CD39– among CD8+CD44+) was seen in hosts receiving UTX-deficient CD8+ Tprog cells, compared with WT cells (Figure 3E). Concomitantly, a decrease in the frequency of pLN Tmed (Ly108–CD39+ among CD8+CD44+) cells was noted in recipients of UTX-deficient Tprog cells (Figure 3E). Together, these findings support a model in which UTX functions in IGRP-specific CD8+ Tprog cells to promote their transition to Tmed cells.

We next asked whether UTX may play a parallel function in CD8+ Tprog cells within the pancreas. To address this, we performed flow cytometric analysis of pancreatic CD8+ T cell subsets in NOD-TCR 8.3 UTXTCD versus NOD-TCR 8.3 WT mice (Supplemental Figure 5A). Similar to pLN CD8+ T cells, pancreatic CD8+ T cells showed altered subset distribution with UTX deficiency. Tprog cells (Ly108+CD39–) were increased, while Tmed cells (Ly108–CD39+) were decreased, in the pancreas of NOD-TCR 8.3 UTXTCD mice compared with NOD-TCR 8.3 WT mice. These findings suggest that UTX’s role in CD8+ Tprog cells in the pancreas mirrors its role in the pLN.

UTX controls chromatin accessibility and transcriptional changes in antigen-specific pLN Tprog cells. Recent studies have demonstrated the importance of epigenetic and transcriptional regulatory programs in controlling the transition of CD8+ T cell states (25). Because UTX is an epigenetic regulator (26), we reasoned that UTX may control the Tprog to Tmed conversion by remodeling chromatin at regulatory elements of target gene loci. To examine this, we performed bulk assay for transposase-accessible chromatin sequencing (ATAC-seq) and RNA-seq in parallel on sort-purified β cell–specific CD8+ Tprog cells from pLNs of either NOD-TCR 8.3 UTXTCD or NOD-TCR 8.3 WT mice. ATAC-seq analysis demonstrated large-scale chromatin accessibility alterations in UTX-deficient CD8+ T cells. Principal component analysis (PCA) plots showed sample clustering by genotype (Figure 4A, top), highlighting the extensive effect of UTX on the chromatin landscape of CD8+ T cells. RNA-seq analysis performed in parallel also showed large-scale transcriptional changes, with PCA analysis of gene expression demonstrating genotype-specific clustering (Figure 4A, bottom). ATAC-seq revealed that 4,075 peaks decreased in accessibility and 8,807 peaks increased in accessibility in NOD-TCR 8.3 UTXTCD progenitors, compared with UTX-sufficient controls (|log2 fold change| >0.5, FDR-adjusted P < 0.05) (Supplemental Data File 2). These differentially accessible peaks corresponded to 6,859 differentially accessible genes. Furthermore, RNA-seq revealed 1,280 decreased and 1,768 increased transcripts in NOD-TCR 8.3 UTXTCD progenitors, compared with UTX-sufficient controls (|log2 fold change| >0.5, FDR-adjusted P < 0.05) (Supplemental Data File 3).

UTX controls chromatin accessibility at progenitor and effector gene loci iFigure 4

UTX controls chromatin accessibility at progenitor and effector gene loci in antigen-specific pLN Tprog cells. (A) PCA analysis of ATAC-seq (top) and RNA-seq (bottom) profiles of sorted Tprog (CD8+ Ly108+ CD39–) cells from pLNs of NOD-TCR 8.3 WT and NOD-TCR 8.3 UTXTCD mice (n = 3/group). (B) Heatmaps of the expression (left, RNA-seq) and chromatin accessibility (right, ATAC-seq) of selected differentially expressed and accessible genes involved in immune function. The color scale indicates the relative expression or accessibility, with red representing higher values and blue representing lower values. (C and D) Gene set enrichment analysis (GSEA) for progenitor signature (Supplemental Data File 4) (C) and effector signature (D) genes in the RNA-seq dataset of Tprog cells from NOD-TCR 8.3 WT and NOD-TCR 8.3 UTXTCD mice. (E) Pathway analysis of differentially accessible genes by ATAC-seq using Enrichr (P value by Fisher’s exact test).

Integrative analysis of ATAC- and RNA-seq identified a significant positive correlation (Pearson R = 0.73, P < 2.2 × 10–16) between genotype-dependent changes in chromatin accessibility and gene expression (Supplemental Figure 6A). These data suggest a direct correlation between UTX-mediated alterations in chromatin accessibility and transcription. Concurrent changes in chromatin accessibility and transcription were observed in genes with known roles in the differentiation and maintenance of stem-like progenitor CD8+ T cells. For instance, NOD-TCR 8.3 UTXTCD Tprog cells demonstrated increased chromatin accessibility, with corresponding increased gene expression, at the locus of Bcl6 (Figure 4B and Supplemental Figure 6B), a TF that prolongs stem-like progenitor persistence (27). Additionally, NOD-TCR 8.3 UTXTCD Tprog cells also showed increased chromatin accessibility and gene expression at the locus of Bach2 (Figure 4B and Supplemental Figure 6B), a transcriptional repressor that promotes the stem-like CD8+ T cell program, while suppressing terminal exhaustion programs (27). Finally, Bcl2, an anti-apoptotic factor that promotes stem-like progenitor cell survival (28), also showed increased accessibility and expression in NOD-TCR 8.3 UTXTCD Tprog cells (Figure 4B and Supplemental Figure 6B). Thus, UTX deficiency is associated with changes at loci that are important in stem-like progenitor maintenance and differentiation.

At the same time, decreased accessibility and reduced expression were seen in NOD-TCR 8.3 UTXTCD Tprog cells at genes important for CD8+ T cell effector function (Figure 4B and Supplemental Figure 6B). These genes include cytolytic molecules (e.g., Gzmb, Gzmc, Fas) important in β cell killing (29); integrins (e.g., Itga4, Itgae) (30, 31) critical in leukocyte islet infiltration; and cytokine/cytokine receptors (e.g., Ifngr1, Cxcr6) (4, 32, 33). Both Dapl1 and Nfatc2, which function together in CD8+ T cell effector function (34), were also less accessible and expressed. Moreover, genes associated with T cell activation (Fosl2, Thy1, Cd9) were also less accessible and downregulated in expression in CD8+ T cells from NOD-TCR 8.3 UTXTCD mice (35–37). Gene set enrichment analysis (GSEA) confirmed these findings, showing upregulated stem-like progenitor and downregulated effector gene signatures in NOD-TCR 8.3 UTXTCD cells (Figure 4, C and D, and Supplemental Data File 4) (4, 9).

Enrichment analysis of differentially accessible genes revealed association with pathways important in stem-like progenitor generation as well as cytolytic effector differentiation and function. For instance, Wnt signaling is critical in the generation and maintenance of stem-like memory T cells (38), and Enrichr pathway analysis of differentially accessible genes revealed upregulation of “Wnt Signaling Pathway” and “Canonical Wnt Signaling Pathway” genes in NOD-TCR 8.3 UTXTCD Tprog cells (Figure 4E). At the same time, “Lymphocyte Differentiation,” “Integrin Cell Surface Interactions,” “Positive Regulation of Lymphocyte Activation,” and other pathways associated with cytolytic effector function were downregulated in NOD-TCR 8.3 UTXTCD Tprog cells (Figure 4E). Together, these findings provide further support that UTX poises chromatin in stem-like Tprog cells for transition to cytolytic effectors.

Integrated analysis of UTX chromatin binding, accessibility, and transcription reveals STAT3 and TCF1 co-occupancy at UTX target genes. The genome-wide changes in accessibility and transcription in UTX-deficient Tprog cells may be attributed either to (a) UTX’s direct regulation of chromatin accessibility and gene expression or (b) secondary changes that result from alterations in other UTX-mediated epigenetic and transcriptional regulators. To identify gene loci directly regulated by UTX, we utilized UTX cleavage under targets and tagmentation assay (CUT&Tag) (39) to identify gene loci bound by UTX on sort-purified NOD-TCR 8.3 WT Tprog cells. Sort-purified NOD-TCR 8.3 UTXTCD Tprog cells were used as a negative control. PCA of UTX CUT&Tag data revealed sample clustering by genotype (Figure 5A). We identified 6,718 UTX-bound peaks (FDR-adjusted P < 0.05), which corresponded to 5,222 distinct genes (Supplemental Data File 5). Genomic annotation of UTX CUT&Tag peaks demonstrated a strong promoter bias, with 64.5% of UTX-bound regions localized within 1 kb of transcription start sites (Figure 5B). This promoter proximal enrichment suggests that UTX primarily engages core regulatory elements to exert its epigenetic functions in Tprog cells.

Integrative analysis of chromatin binding, accessibility, and transcriptionFigure 5

Integrative analysis of chromatin binding, accessibility, and transcription reveals that STAT3 and TCF1 cobind UTX-target genes. (A) PCA analysis of UTX CUT&Tag from sorted Tprog (CD8+ Ly108+ CD39–) cells from pLNs of NOD-TCR 8.3 WT and NOD-TCR 8.3 UTXTCD mice. (B) Location of UTX-bound peaks. (C) Venn diagram outlining overlapping differentially accessible (DA) genes identified by ATAC-seq and differentially expressed (DE) genes identified by RNA-seq. (D) Representative gene tracks from the UCSC Integrated Genome Browser of anti-UTX CUT&Tag, ATAC-seq, and RNA-seq of effector genes, Gzmb and Cxcr6, and progenitor genes, Bach2 and Bcl2. The y axis depicts counts per million (CPM). (E) Transcriptional factors were bound to the overlapping genes identified by UTX datasets. Overlapping genes were input into Enrichr for ChEA3 analysis. (F) Venn diagram outlining overlapping genes bound by UTX, TCF1, and STAT3 (TCF1 ChIP-seq: GSE73240, STAT3 ChIP-seq: GSE217374). (G) Gene tracks from the UCSC genome browser to demonstrate the aligned region bound by UTX, TCF1, and STAT3. The y axis depicts CPM.

We utilized this UTX CUT&Tag dataset, the ATAC-seq dataset (Figure 4B), and the RNA-seq dataset (Figure 4B) to identify 502 gene loci that are UTX-bound, differentially accessible, and differentially expressed in UTX-deficient Tprog cells (Figure 5C). These UTX-bound genes included stem-like progenitor-associated genes (i.e., Bach2, Bcl2, Bcl6) that are increased in accessibility and transcription within NOD-UTXTCD Tprog cells (Figure 5D and Supplemental Figure 7A), suggesting that UTX binds directly to stem-like progenitor-associated genes to decrease accessibility and repress transcription at these loci. Additionally, UTX-bound genes included mediator-associated genes (i.e., Gzmb, Cxcr6, Thy1) that are decreased in accessibility and transcription within NOD-UTXTCD Tprog cells (Figure 5D and Supplemental Figure 7A). These analyses demonstrate that in antigen-specific Tprog cells, UTX poises chromatin to repress transcription at key Tprog genes and to promote transcription at effector genes.

While UTX has intrinsic histone demethylase activity, our data demonstrate that UTX’s demethylase activity is dispensable in T1D pathogenesis (Supplemental Figure 1B). An alternative mechanism by which UTX exerts its regulatory effects is through interactions with TFs (40). To identify TF binding partners of UTX, we used a TF enrichment analysis tool (ChEA3 in Enrichr) to prioritize TFs potentially responsible for the observed 502 UTX-bound, differentially accessible, and differentially expressed target genes (Figure 5E) (41). Highly associated TFs included (a) TCF1, a key regulator of stem-like progenitors, (9) and (b) STAT3, a TF implicated in Tprog to effector cell conversion and a key TF in T1D pathogenesis (10–12). These findings suggest the possibility that UTX may function in concert with TCF1 and STAT3 to regulate differentiation of Tprog cells to an effector state.

We next integrated our UTX CUT&Tag dataset with publicly available chromatin immunoprecipitation datasets to determine whether gene loci may be co-occupied by UTX, TCF1, and STAT3 proteins. Cross-referencing of UTX-bound genes with TCF1-bound (GSE73240) and STAT3-bound (GSE217374) genes showed substantial overlap of 1,768 genes (Figure 5F). These overlapping genes included progenitor-associated genes (Bcl2, Bach2, Bcl6, and Lef1) and mediator-associated genes (Cxcr6, Gzmb, Ifngr1, and Thy1) that are differentially accessible and differentially expressed in NOD-UTXTCD CD8+ Tprog cells, compared with NOD-WT cells. Moreover, comparison of UTX-bound, TCF1-bound, and STAT3-bound peaks showed a high degree of overlap in multiple genes (Figure 5G and Supplemental Figure 8A). Binding by UTX, TCF1, and STAT3 was noted at key effector-associated genes (e.g., Gzmb, Cxcr6, Runx3, and Ifng) as well as progenitor-associated genes (e.g., Bach2, Ccr7, and Lef1), suggesting co-occupancy of UTX, TCF1, and STAT3 at these target gene loci. Collectively, these data suggest that UTX cooperates with TCF1 and STAT3 to influence the transition of antigen-specific Tprog cells to an effector state.

UTX promotes differentiation of human stem cell memory CD8+ T cells into a terminally differentiated effector state through binding with TCF1 and STAT3. Recent work has associated T1D in humans with increased circulating CD8+ T memory stem cells (TSCM), a long-lived, self-renewing β cell–specific population (2, 42, 43). TSCM cells play a key role in T1D pathogenesis by giving rise to terminally differentiated effector/mediator (TTE) cells that ultimately kill insulin-producing β cells. Thus, the TSCM (CCR7+CD45RA+CD95+) population in patients with T1D may have a parallel role to the Tprog population in NOD mice, while the TTE (CCR7–CD45RA+CD95+) population in patients with T1D may have a parallel role to the Tmed population in NOD mice (42, 43).

To test whether UTX controls the TSCM to TTE conversion, we utilized CRISPR/Cas9 to edit the UTX locus in CD8+ T cells isolated from PBMCs from a patient with T1D. We confirmed efficient knockdown of UTX protein expression using UTX-specific sgRNAs compared with a nontargeting control (NTC sgRNA) (Figure 6A). Following a 7-day culture with homeostatic cytokines (IL-2, IL-7, IL-15), we observed an increased frequency of TSCM cells (CCR7+CD45RA+) and a corresponding decrease in TTE cells (CCR7–CD45RA+) in UTX-deficient CD8+ T cells relative to controls (Figure 6B). This altered distribution supports a cell-intrinsic role for UTX in governing TSCM to TTE conversion in human CD8+ T cells, indicating a conserved, cross-species function for UTX.

UTX regulates human stem cell memory CD8+ T cell differentiation into the tFigure 6

UTX regulates human stem cell memory CD8+ T cell differentiation into the terminally effector state and interacts with TCF1 and STAT3. (A) Representative flow cytometric plot of CD8+ T cells from patients with T1D after CRISPR-Cas9 editing with NTC (non-targeting control) sgRNA or UTX-targeting sgRNA. (B) Representative flow cytometric plots (left) and average frequency (right) of TSCM and TTE cells among CD8+CD95+ peripheral blood cells from patients with T1D. Cells were edited with either NTC sgRNA or UTX-targeting sgRNA. (C) In vitro binding assay to show the interaction of UTX-TCF1 (left) and UTX-STAT3 (right) in HEK-293T cells by cotransfection and coimmunoprecipitation. (D) Representative flow cytometric histogram plot of TCF1 expression in CD8+ T cells treated with DMSO or 5 μM TWS119 supplemented with IL-7 (10 ng/mL) and IL-21 (25 ng/mL) for 7 days. (E) Frequencies of TSCM and TTE cells within CD8+CD95+ T cells treated with DMSO or 5 μM of TWS119 for 3 days. Each dot represents a biological replicate (n = 7). **P < 0.01; paired Student’s t test. (F) Representative flow cytometric histogram plot of CD8+ T cells from patients with T1D after CRISPR/Cas9 editing with nontargeting control (NTC) sgRNA or STAT3-targeting sgRNA. (G) Frequencies of TSCM and TTE cells within CD8+CD95+ T cells after CRISPR/Cas9 editing with sgSTAT3 versus a NTC. Left: TSCM; right: TTE. Each dot represents a biological replicate (n = 3). **P < 0.01; paired Student’s t test. (H) Model of how UTX forms a complex with TCF1 and STAT3 to modulate the progenitor and effector programs in promoting T1D development.

Given that our integrative analysis suggested a high degree of cooperativity between UTX, TCF1, and STAT3 (Figure 5, E–G), we utilized a coimmunoprecipitation approach to assess the binding of UTX to TCF1 and STAT3. HEK-293T cells were cotransfected with epitope-tagged constructs encoding UTX in combination with either TCF1 or STAT3, and subsequent immunoprecipitation demonstrated interactions between UTX and both TCF1 and STAT3 (Figure 6C). In line with this finding, endogenous UTX protein coimmunoprecipitated with TCF1 and STAT3 in Jurkat cells (Supplemental Figure 9A). These data demonstrate that UTX directly binds critical TFs important in progenitor specification (9) and progenitor-to-effector differentiation (10–12).

TCF1 expression is induced by inhibitors of glycogen synthase kinase 3 β, such as TWS119 (9). Consistent with TCF1’s role in enforcing progenitor formation and maintenance, treatment of CD8+ T cells from patients with T1D with TWS119 resulted in the induction of TCF1 (Figure 6D) and an increased frequency of TSCM and a decreased frequency of TTE cells (Figure 6E). Moreover, STAT3 drives progenitor T cell conversion to effectors (11), and editing of the STAT3 locus in CD8+ T cells from patients with T1D resulted in accumulation of TSCM cells and decreased TTE cells (Figure 6, F and G). Based on these data, we propose a mechanistic model wherein UTX interacts with STAT3 to enhance effector gene transcription necessary for the progenitor-to-effector transition, while simultaneously binding TCF1 to suppress its progenitor-maintaining functions during differentiation (Figure 6H). These factors function in tandem at gene loci important in effector function and progenitor identity, an insight that enhances our understanding of the molecular mechanisms underpinning autoimmune chronicity and offers potential avenues for targeted therapeutic interventions in T1D.

Discussion

For patients with T1D, the persistence of the β cell autoimmune response results in a lifetime of insulin dependence. As a consequence, patients are predisposed to cardiovascular disease and other T1D-associated complications, including shortened life expectancy (44). Accumulating evidence points to a key role for stem-like Tprog cells in prolonging the autoimmune response (2, 3). These long-lived Tprog cells continually repopulate the pool of terminally differentiated, cytolytic CD8+ T cells that destroy β cells. The mechanisms controlling the conversion of Tprog cells to cytolytic effectors, however, remain incompletely understood. Here, we identify UTX as an epigenetic regulator that primes Tprog cells for transition to cytolytic effectors. UTX exhibits regulatory function in CD8+ T cell differentiation through its interactions with TCF1 and STAT3 TFs, independent of its intrinsic histone demethylase activity. Taken together, these findings suggest that this UTX:TCF1:STAT3 regulatory complex may be targeted therapeutically to disrupt the chronic autoimmune process of T1D.

In β cell–specific Tprog cells, UTX represses transcription at gene loci (Bcl6, Bach2, Bcl2) well-described for their roles in the differentiation and maintenance of stem-like progenitors. At the same time, UTX organizes chromatin for enhanced transcription at multiple effector loci (e.g., Gzmb, Thy1, Cxcr6) in CD8+ Tprog cells. These data point to UTX’s dual role of repressing stem-like progenitor maintenance in favor of promoting a cytolytic effector CD8+ T cell program. Our findings suggest that coordination with TCF1 and STAT3, TFs with respective functions in progenitor specification (9) and progenitor-to-effector differentiation (10–12), is critical for the function of UTX in diabetogenic CD8+ T cells.

Genetic association studies in T1D have been instrumental in identifying pathogenic mechanisms. The Type 1 Diabetes Genetics Consortium (T1DGC) reported that a TCF7 C883A polymorphism was associated with T1D in patients who do not carry the high-risk HLADR3/4 genotype (7). This finding corroborated a previous report from the T1DGC Rapid Response Project that linked T1D with the TCF7 locus (8). In addition to TCF7, alterations in STAT3 also have a notable effect on T1D susceptibility (45). Approximately 30% of patients with gain-of-function STAT3 mutations develop T1D (46), and NOD mice with a human gain-of-function STAT3 mutation develop accelerated T1D (10, 12). Indeed, our findings indicate that UTX forms a complex with TCF1 (encoded by TCF7) and STAT3 to promote the differentiation of progenitor CD8+ T cells into an effector state, contributing to the autoimmune response in T1D.

How STAT3 contributes to T1D pathogenesis has been the subject of much interest. Early studies suggested that STAT3 gain-of-function mutations result in changes to the distribution of CD4+ T cell subsets, noting increased ratios of T helper 17 (Th17) cells to Tregs (46). In contrast, recent studies have demonstrated alterations in the CD8+ T cell compartment, such that effector CD8+ T cells were increased in mice harboring human STAT3 gain-of-function mutations (10, 12). While possible that STAT3-mediated changes to both CD4+ and CD8+ T cells may underlie the promotion of T1D, our findings support the important role of STAT3 in CD8+ T cell differentiation by coordination with UTX and TCF1.

While our data demonstrate that UTX promotes the diabetogenic capacity of CD8+ T cells and the conversion of CD8+ Tprog to Tmed cells, we cannot exclude the possibility that UTX also plays a role in CD4+ T cells during T1D pathogenesis. Indeed, UTX has previously been shown to upregulate IL-6R expression in CD4+ T cells, promoting IL-6–dependent Tfh differentiation in the context of chronic lymphocytic choriomeningitis virus (LCMV) infection (18). However, we did not see a difference in the frequency of CD4+ Tfh cells in the pLNs of NOD-WT versus NOD-UTXTCD mice. We speculate that this reflects a difference in the dependence of these 2 model systems on IL-6. While IL-6 is required for late-stage control of chronic LCMV infection (47), IL-6 deficiency does not impair diabetes development in NOD mice (48). This suggests that other cytokines besides IL-6 may play a role in the differentiation of Tfh cells in NOD mice. Indeed, IL-21 has been identified as a redundant cytokine to IL-6 in the induction of Tfh cells (49). Additionally, CD4+ T cells with stem-like features that express TCF1 have recently been described in NOD mice (19), and whether UTX may also regulate this CD4+ T cell subset requires further investigation.

Between 2002 and 2012, the incidence of T1D in youth increased by 1.4% per year (50), a rise that prompts us to question what factors may be driving the development of autoimmune disease beyond genetic susceptibility. Epigenetic alterations have been indicated as the possible bridge between environmental influence and genetics in the development of disease, such that environmental cues induce alterations to gene expression without changes to the DNA sequence itself (51). In this study, we show that diabetogenic CD8+ T cells and their developmental trajectory are orchestrated by the epigenetic regulator UTX. Our findings suggest that therapies blocking cytolytic effector CD8+ T cell differentiation and function may be effective therapeutic strategies for T1D. Therapies that modulate epigenetic mechanisms are already in use for cancer (52), and our data reveal the UTX:TCF1:STAT3 complex as a potential therapeutic target for chronic autoimmunity.

Methods

Sex as a biological variable. Only females were included in these studies since UTX is X-linked and expression of the Y-linked homolog UTY in males could confound analyses.

Mice. NOD/ShiLtJ (NOD; JAX:001976) and NOD.Cg-Prkdcscid/J (NOD.SCID; JAX:001303) mice were purchased from The Jackson Laboratory. NOD-UTXfl/fl.LckCre+ (NOD-UTXTCD) mice were generated by backcrossing B6-UTXfl/fl LckCre+ mice to NOD mice >10 generations (53). We confirmed that the 26 identified diabetes associated (Idd) loci were derived from recipient NOD strain by congenic fine mapping (MegaMUGA). Cre-negative littermates were used as UTX-sufficient, WT controls (NOD-WT). NOD-TCR 8.3 UTXTCD were generated by crossing NOD-UTXTCD mice with NOD.Cg-Tg (TcraTcrbNY8.3)1Pesa/DvsJ (NOD-TCR 8.3; JAX:005868) mice. All mice were housed in a specific pathogen–free barrier facility at UCLA. Experiments were performed in compliance with UCLA Animal Research Committee regulations.

The NOD.UTXDMD mice were generated at the UNC Animal Models Core. These mice have mutations that result in amino acid alterations at H1146A and E1148A that inactivate the demethylase activity of UTX (54). These mutations were achieved by injecting NOD pronuclei with gRNA:Cas9 complexes that target introns flanking exon24, which encodes the JmjC domain, along with a plasmid donor encoding the mutated exon 24. Single-cell mouse embryos were then surgically implanted into the oviducts of pseudopregnant recipient NOD mice. The resulting pups were further backcrossed to NOD prior to intercrossing to generate female homozygous mice for use in these studies. Mice with the knockin allele were identified by PCR and sequencing using PCR primers: (Utx-Intron23-ScF2: CACGCATTTCCCAGC ACTTG; Utx-Int23-ScR2: CCTACTTTTCACAGAAGTCATTCAAAACAC), and sequencing using primer: (Utx-Int23-SqF1: TAACAAATATATCTTATTGGGCACC). These mice were housed in specific pathogen–free facilities at UNC Chapel Hill, and experiments performed with them were approved by the Institutional Animal Care and Use Committee at UNC Chapel Hill.

Assessment of diabetes. Mice were monitored for diabetes at least once per week using urine glucose strips (Ascensia Diabetes Care). Mice were considered diabetic after 2 consecutive urine tests matched with the color of glucose concentration ≥250 mg/l.

Adoptive T cell transfer. All adoptive transfer experiments used NOD.SCID mice as hosts and were performed by intravenous tail vein injections. For CD8+ T cell transfers, splenic CD8+ T cells of NOD-WT or NOD-UTXTCD mice were isolated by the EasySep Mouse CD8+ T Cell Isolation Kit (STEMCELL Technologies, 19853), and splenic CD4+ T cells from NOD-WT mice were isolated by EasySep Mouse CD4+ T Cell Isolation Kit (STEMCELL Technologies, 19852). 1 × 106 splenic CD8+ T cells were cotransferred with 1 × 106 splenic CD4+ T cells into the host. Diabetes development was assessed twice a week.

For CD8+ Tprog transfer, Ly108+ CD39– cells among CD8+ CD44+ Tprog cells were sorted from the pLNs of NOD-TCR 8.3 UTXTCD or NOD-TCR 8.3 WT mice. 250,000 CD8+ Tprog cells were cotransferred with 1 × 106 splenic WT CD4+ T cells into the hosts. Three weeks after transfer, pLN CD8+ T cells were analyzed by flow cytometry.

Histology and insulitis scoring. H&E staining of pancreas tissues was done by UCLA Translational Pathology Core Laboratory. Insulitis for each pancreatic islet is scored based on the percentage of islet infiltrated by immune cells: 0, no infiltration; 1, 0%–25% infiltration; 2, 25%–50% infiltration; 3, 50%–75% infiltration; 4, 75%–100% infiltration.

Immune cell isolation. Mice were euthanized by CO2. Lymph nodes and spleens were mechanically disrupted with the back of a 1 mL syringe, filtered through a 40 μm strainer, and subjected to ACK lysis for 1 minute. Cells were washed once with PBS. Pancreas digestion was adapted from existing protocols. In brief, 3 mL collagenase type IV solution (2 mg/mL) with DNaseI (10 U/mL) in HBSS (Gibco 14025-092) supplemented with 10% fetal bovine serum (FBS) and DNaseI (10 U/mL) was injected into the clamped pancreatic duct. Perfused pancreases were then excised and incubated in 4 mL of the collagenase solution at 37°C for 30 minutes. The digested pancreas was then washed using 10 mL HBSS with 10% FBS and spun down at 300g for 3 minutes, 2 times, followed by mechanically breaking up the pancreas. Then, tissue was passed through a 40 μm strainer and washed with HBSS with 10% FBS, and spun down at 400g for 5 minutes. Finally, the pellet was resuspended in FACS buffer for antibody staining.

Flow cytometry and cell sorting. Cells were analyzed for surface markers using fluorophore-conjugated antibodies. Cell surface staining was performed in FACS buffer (2% FBS and 2 mM EDTA in PBS) for 30 minutes at 4°C. Intranuclear protein staining, including UTX, H3K27me3, and TCF1, was performed by fixing and permeabilizing using the eBioscience Foxp3/Transcription Factor kit, followed by the primary rabbit antibody, goat anti-rabbit IgG H&L (Abcam), which was used as the secondary antibody.

H-2Kd/NRP-V7 (KYNKANFL) tetramer was obtained from the NIH Tetramer Core Facility. Tetramer staining was performed with two steps: cells were stained with tetramer in PBS solution (1:200) for 30 minutes at room temperature, followed by staining with surface markers for 30 minutes at 4°C. For intracellular cytokine staining, cells were stimulated with PMA (50 ng/mL), ionomycin (1 μg/mL), Brefeldin A (1×), and monensin (1×) for 4 hours. Cells were stained with surface antigen-targeting antibodies and then fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, 554714) for subsequent cytokine staining. Flow cytometry was performed on an LSRII Fortessa, and FACS sorting was performed on an ARIA or ARIA-H instrument (BD Biosciences) at the UCLA Broad Stem Cell Research Center Flow Cytometry Core. The data were analyzed with FlowJo v10.7.2 (TreeStar). Antibodies used are shown in Supplemental Table 1.

Single-cell RNA analysis. pLN scRNA-seq data were clustered using Seurat package (version 4.4.0). Differential gene markers of each cluster are computed using the FindAllMarkers function of Seurat. Immune cell types are defined based on their canonical markers (Supplemental Data File 1A). CD8+ T cell clusters, including clusters with mixed CD8+ and CD4+ T cells, were reintegrated after updating their list of variable genes, scaled, and reclustered (Supplemental Data File 1B). Clusters containing cells with high mitochondrial, ribosomal, and noncoding RNAs were deemed to be low quality and were removed from our subsequent analyses. The clustering of CD4+ T cells was performed in the same manner (cluster markers in Supplemental Data File 1C).

Uniform manifold approximation and projection (UMAP) plots, violin plots, dot plots, box plots visualizations were created using functions from the Seurat package or ggplot2 package (version 3.5.1). Cell count frequency was calculated by normalizing cell count from each cluster to the total cell count of a specified cell type (e.g. CD8+ T cells or CD4+ T cells) in each sample. Pseudotime analysis was performed using the Slingshot package (version 2.4.0). Heatmaps are generated using ComplexHeatmap package (2.12.1)

Isolation of human CD8+ T cells. This study was conducted with approval from the institutional review boards of the University of California, Los Angeles; written informed consent was obtained. All donors included in this study were female. For adult donors with T1D, blood was collected through UCLA endocrine clinics. For healthy adult donors, blood was collected through the UCLA Virology Core Laboratory. Collected blood was then performed PBMC isolation, diluted with sterile PBS (Thermo Fisher Scientific). 35 mL of diluted blood was then overlayed with 15 mL of Ficoll-paque (GE Healthcare). The gradient was centrifuged at 400g with no brake for 30 minutes at room temperature. The PBMC interphase layer was collected, washed with FACS buffer, and centrifuged at 400g for 5 minutes, and cryopreserved in liquid nitrogen. For CD8+ T cell stimulation, PBMC CD8+ T cells were enriched with EasySep Human CD8+ T Cell Isolation Kit (STEMCELL Technologies, #17953).

T cell stimulation. Mouse and human CD8+ T cells (1 × 106/mL) were cultured in 10% FBS complete RPMI + human IL-2 (50 U/mL). Medium for mouse CD8+ T cells culture was supplemented with 1x 2-Mercaptoethanol (Gibco, 21985023). CD8+ T cells were plated in 48-well nontissue culture plate for stimulation. Mouse CD8+ T cells were stimulated by Dynabeads Mouse T-Activator CD3/CD28 and human CD8+ T cells were stimulated by Dynabeads Human T-Activator CD3/CD28. After stimulation, mouse and human CD8+ T cells were analyzed by intracellular and surface protein staining. For TWS119 studies, 2 × 105 human CD8+ T cells were stimulated with Dynabeads Human T-Activator CD3/CD28 under the condition of either DMSO or 5 μM TWS119 inhibitors to activate the Wnt/B-catenin pathway. After 3 days of stimulation, TSCM and TTE populations were identified by using flow cytometry with CD45RA and CCR7 markers.

Genome editing in human resting CD8+ T cells by CRISPR. Freshly isolated human CD8+ T cells (2 × 106) were washed twice with PBS and resuspended in 20 μL of buffer T (Thermo Fisher, Neon System). In parallel, synthetic sgRNAs (Synthego) were incubated with recombinant NLS-Cas9 (QB3 MacroLab) for 15 minutes at 37°C, at a ratio of 1:2.5 (40 pmol Cas9 protein per 100 pmol gRNA) to form the CRISPR/Cas9 gRNA RNP complex. CD8+ T cells were then added to the RNP complex and electroporated using the Neon NxT Electroporation System with the following settings: 2,100 volts, 20 ms, and 1 pulse. Afterward, 1 mL prewarmed RPMI was added to the cells to allow recovery for 15 minutes at 37°C. Subsequently, complete RPMI medium supplemented with IL-7 (Peprotech; 200-07) and IL-15 (Peprotech; 200-15) (2 ng/mL each) was added. The sequence of sgRNA targeting the human KDM6A gene is as follows: UUGGAUAAUCUUCCAAUAAG and CAGCAUUAUCUGCAUACCAG. Scramble gRNA (Synthego) was used as a negative control. The sequences of the sgRNA used to target the STAT3 locus are GCAGCUUGACACACGGUACC and AAUGGAGCUGCGGCAGUUUC.

RNA-seq library construction and data processing. Total RNA was isolated from sort-purified CD8+ progenitors (Ly108+CD39–) using the Quick RNA MiniPrep Kit (Zymo). RNA quality was verified using TapeStation analysis. RNA-seq libraries were generated by UCLA Technology Center for Genomics & Bioinformatics (TCGB) and sequenced on a Novaseq X Plus (paired end, 2 × 50 bp). RNA-seq analysis was carried out by first checking the quality of the reads using FastQC. Then, they were mapped with HISAT2 (version 2.2.1) to the mouse genome (mm10). The counts for each gene were obtained by featureCounts package. Differential expression analyses were carried out using DESeq2 (version 1.24.0) with default parameters. Genes with absolute fold change difference of >1.5 with an FDR-adjusted P value < 0.05 were considered significantly differentially expressed.

CUT&Tag library preparation and data processing. CD8+ islet-specific progenitors (Ly108+CD39–) was sorted by AIRA sorting, and 300,000 progenitors were used as input for UTX CUT&Tag library preparation. After sorting, nuclei were isolated with cold nuclear extraction buffer (20 mM HEPES, pH 7.9, 10 mM KCl, 0.1% Triton X-100, 20% glycerol, 0.5 mM spermidine in 1× protease inhibitor buffer) and incubated with activated concanavalin A–coated magnetic beads (Polysciences, 86057-3) in PCR strip tubes at room temperature for 10 minutes. A 1:100 dilution of primary antibody (anti-UTX Cell Signaling Rabbit monoclonal antibody no. 33510 or IgG isotype control: Cell Signaling Technology, 3900S) in antibody buffer (20 mM HEPES pH 7.5; 150 mM NaCl, 0.5 mM spermidine, 1× protease inhibitor cocktail (Roche), 0.05% digitonin, 2 mM EDTA, 0.1% BSA) was added, and nuclei were incubated with primary antibodies overnight at 4°C. The next day, the strip tubes were incubated on a magnetic tube holder, and supernatants were discarded. Secondary antibody (guinea pig anti-rabbit IgG; Fisher Scientific, NBP172763) was added diluted at 1:100 in Dig-Wash (20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM spermidine, 1× protease inhibitor cocktail, 0.05% digitonin), and nuclei were incubated for 1 hour at room temperature. Nuclei were washed 4 times in Dig-Wash and then incubated with a 1:20 dilution of pAG–Tn5 adaptor complex (EpiCypher) in Dig-300 buffer (1× protease inhibitor cocktail, 20 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM spermidine) for 1 hour at room temperature. To stop tagmentation, 25 μL Dig-300 buffer with 10 μL 1 M MgCl, 7.5 μL 0.5 M EDTA, 2.5 μL 10% SDS, and 5 μL 10 mg ml−1 proteinase K was added to each reaction and incubated at 55°C for 1 hour. DNA was extracted by phenol:chloroform:isoamyl alcohol separation. DNA was barcoded and amplified using the following conditions: a PCR mix of 25 μL NEBNext 2× mix, 2 μL each of barcoded forward and reverse 10 μM primers, and 21 μL of extracted DNA was amplified at 58°C for 5 minutes, 72°C for 5 minutes, 98°C for 45 seconds, 16× 98°C for 15 seconds followed by 63°C for 10 seconds, and 72°C for 1 minute. Amplified DNA libraries were purified by adding a 1.3× volume of KAPA pure SPRI beads (Roche) to each sample and incubating for 10 minutes at 23°C. Samples were placed on a magnet, and unbound liquid was removed. Beads were rinsed twice with 80% ethanol, and DNA was eluted with 25 μL TE buffer. All individually i7-barcoded libraries were mixed at equimolar proportions for sequencing on an Illumina Novaseq X Plus sequencer with 50 bp pair-end sequencing.

The UTX CUT&Tag, Stat3-ChIP (GEO GSE217374), and TCF1-ChIP (GEO GSE73240) data analyses were carried out using the raw fastq data file. The sequencing quality of libraries was assessed by FastQC. Ends of sequencing reads were trimmed by Cutadapt. Bowtie2 (version 2.4.2) was used to align the sequencing reads to the mouse genome, mm10. PCR duplicates were removed using Picard MarkDuplicates. The uniquely mapped reads were used to call peaks with MACS2 using a P value cutoff of 0.01. ChIPseeker was used for peak annotation. Figures of coverage tracks were exported from bigwig read alignment files using the UCSC Genome Browser.

Coimmunoprecipitation and Western blot. For the in vitro binding assay, 3.6 × 106 of HEK-293T cells (ATCC) were plated on a 10 cm plate 24 hours before transfection. Transfection was performed by mixing plasmids expressing Flag-tag UTX (Addgene plasmid 17438) and HA-Tag TCF1 (Addgene plasmid 40620) with the transfection reagent, TransIT-293 (Mirus), at a 1:2 (DNA–transfection reagent) ratio. For the STAT3 interaction, Flag-tag STAT3 (Addgene plasmid 8709) (55) or empty Flag construct was cotransfected with HA-UTX (Addgene plasmid 24168) (56). Twenty-four hours after transfection, cells were harvested and processed with Nuclear Complex Co-IP Kit (Active Motifs). 500 μg of total protein was used for coimmunoprecipitation, and anti-FLAG M2 magnetic beads (Millipore) were added to the samples for overnight incubation. After incubation, samples were washed 6 times with wash buffer and eluted in 2x LDS sample buffer, boiled at 95°C for 5 minutes. Pulldown samples were stored at –80°C, and a Western blot was performed for analysis.

For the in vitro binding assay with Jurkat cells (gift from Christopher Seet, UCLA), 8 × 106 Jurkat cells were used to isolate nuclear protein lysate with the Nuclear Complex Co-IP Kit. 500 μg of total protein was used for coimmunoprecipitation. 7 μg of UTX antibodies were added to pull down the protein complex, and rabbit IgG antibodies (7 μg) served as negative controls for overnight incubation at 4°C. After overnight incubation, 20 μL Protein A (Cell Signaling Technology) for rabbit IgG was added to the protein lysate and incubated at 4°C for 1 hour. After incubation, samples were washed 6 times with wash buffer and then eluted in 2× LDS sample buffer. They were subsequently boiled at 95°C for 5 minutes. Pulldown samples were stored at –80°C, and a Western blot was performed for analysis.

Protein lysates were prepared in LDS sample buffer with 10 mM DTT. Samples were loaded and run onto precast gels, NuPAGE Bis-Tris Mini Protein Gels, 4–12%. Thereafter, gels were transferred to PVDF membrane with 10% methanol transferring buffer at 30 V for 60 minutes. Membranes were blocked in 5% skim milk in TBS-T buffer for 1 hour at room temperature on a rocking platform. After blocking, membranes were incubated overnight with the following antibodies: HA-Tag (C29F4) rabbit mAB (CST, 3724) and Monoclonal ANTI-FLAG M2 antibody (CST 8146 or 14793). Diluent and dilutions were determined following the manufacturer’s instructions. The following day, membranes were incubated with Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP (Abcam, ab205718) or Anti-mouse IgG, HRP-linked Antibody (CST, 7076) or infrared conjugated secondaries (IRdye 800CW Goat anti-Mouse IgG: LICOR 926-32210 or Goat anti-Rabbit 680LT: LICOR 926-68021) for 1 hour at room temperature on a rocking platform.

ATAC-seq library construction and data processing. CD8+ progenitors (Ly108+CD39–) isolated from the pLNs of NOD-TCR 8.3 WT (n = 3) and NOD-TCR 8.3 UTXTCD (n = 3) mice were purified by cell sorting. Each genotype has 3 biological replicates. 50,000 cells were used for ATAC-seq library preparation based on published Omni-ATAC protocol (57). In brief, the sorted cells were treated with lysis buffer for 3 minutes on ice, and the extracted nuclei were resuspended in the transposition mix containing 2.5 μL transposase (Illumina) and incubated at 37°C for 30 minutes with 1,000 rpm shaker. The products were purified with DNA Clean and Concentrator-5 Kit (Zymo Research) and then amplified with PCR for 11 cycles using barcoding primers provided by previous literature. PCR products were assessed for size selection using AMPure XP Bead (Beckman coulter) to purify DNA fragments from 150–1,000 bp. The concentration and quality control were measured by Qubit and Tapestation. The libraries were pooled based on molar concentrations and sequenced on Novaseq X Plus (paired-end, 2 × 50 bp).

The sequencing quality of the libraries was assessed by FastQC (0.11.9), followed by the trimming process using Cutadapt (4.6). Bowtie2 (2.4.2) was used to align the sequencing reads to the mm10 mouse genome, and only uniquely mapped reads (MAPQ30) were retained for downstream analyses. SAMtools (1.15.0) was used to convert SAM files into BAM files and sort BAM files. Picard MarkDuplicates (2.25) was used to remove duplicate reads in the BAM files. MACS2 (2.2.9) was used for ATAC-seq peak calling (paired-end mode, FDR-adjusted q < 0.01). For differential binding analysis, we used the Diffbind (3.20) package to determine differentially bound peaks found in all replicates for WT versus UTXTCD with the DESeq2 method. Peaks/regions identified as differentially accessible were annotated using the annotatepeaks.pl function from the HOMER analysis package. FeatureCounts Package (2.0.3) was used to count the number of reads that overlap each peak per sample. Chromatin regions were considered as significantly differentially accessible at a threshold of absolute log2 fold change difference in accessibility >0.5 and FDR-adjusted P < 0.05. Count-per-million-normalized bigwig files were generated for visualization using Deeptools’ (3.5.6) BamCoverage function. Figures of coverage tracks were exported from bigwig read alignment files using the UCSC Genome Browser.

Statistics. Statistical analysis was performed using GraphPad Prism 9 or R for scRNA sequencing analysis. Unpaired 2-tailed t tests were used to compare 2 groups while 2-tailed paired t tests were used for matched samples. For T1D incidence curves, a log-rank (Mantel-Cox) test was used. Benjamini-Hochberg–adjusted (also known as FDR method) P values were reported for differentially expressed genes, Pathway Analysis by Enrichr, and gene set enrichment analysis by GSEA. Fold changes were calculated as (B-A)/A, where A and B represent expression values of a particular gene in the two conditions being compared, and A is the control. A P value of less than 0.05 was considered significant, and data are presented as mean ± SEM.

Study approval. All experiments with mice were approved by the UCLA Animal Research Committee.

Data availability. Bulk RNA-seq (GEO GSE282227), bulk ATAC-seq (GEO GSE282227), and scRNA-seq (GEO GSE283268) data were deposited in the National Center for Biotechnology Information GEO database. Values for all data points in the graphs are reported in the Supporting Data Values file. The paper did not include any original code. Software and packages are listed in the key resources table and Methods. All the bioinformatic analyses scripts are available upon request from MAS.

Author contributions

HCC, MGL, WH, and MAS conceptualized the study. HCC, LAK, SZ, ZZ, and WH performed bioinformatics analysis. HCC, MFB, HHW, KBS, LAK, DS, SZ, ECM, SS, CLHP, XY, JGO, and NMW performed the experiments. HCC, MFB, KBS, ECM, MGL, WH, and MAS contributed to data visualization. MFB, CLHP, RCC, DJC, SDM, and CMR consented patient donors with T1D. MAS wrote the original draft. MFB, MGL, WH, and MAS reviewed and edited the final manuscript. MS, EP, CB, LY, AAB, and JKW performed experiments.

Funding support

This work is the result of NIH funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central.

  • NIH grants U19AI181729 and R01DK119445 to MAS, MGL, and WH; R01DE030530 to KBS; R01AI143894 to MS and JKW; and R01CA236910 to WH.
  • US Department of Defense W81XWH2110919 awards to MS and JKW.
Supplemental material

View Supplemental data

View Supplemental data set 1

View Supplemental data set 2

View Supplemental data set 3

View Supplemental data set 4

View Supplemental data set 5

View Unedited blot and gel images

View Supporting data values

Acknowledgments

The authors thank the NIH Tetramer Core (Atlanta, Georgia, USA) for providing the NRP-V7/H-2Kd PE tetramer. We also thank the Flow Cytometry Core at UCLA for technical support and the TCGB at UCLA for the help with scRNA-seq, bulk RNA-seq, and ATAC-seq. We thank members of the UNC Animal Models Core and Director Dale O. Cowley for generating the NOD.UTXDMD mice.

Address correspondence to: Maureen A. Su, Department of Microbiology, Immunology, and Molecular Genetics and Pediatrics, UCLA David Geffen School of Medicine, 615 Charles E. Young Dr. South, BSRB 254, Los Angeles, California, 90095, USA. Phone: 919.597.0777; Email: masu@mednet.ucla.edu. Or to: Willy Hugo, Department of Medicine, Dermatology, UCLA David Geffen School of Medicine, 700 Tiverton Dr., Factor Building 9-240M, Los Angeles, California, 90095, USA. Phone: 310.794.6083; Email: hwilly@mednet.ucla.edu. Or to: Melissa G. Lechner, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, UCLA David Geffen School of Medicine, 10833 Le Conte Ave., CHS 32-176, Los Angeles, California, 90095, USA. Phone: 314.651.4199; Email: mlechner@mednet.ucla.edu.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Copyright: © 2025, Chen et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2026;136(4):e196325.https://doi.org/10.1172/JCI196325.

References
  1. Bluestone JA, et al. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–1300.
    View this article via: CrossRef PubMed Google Scholar
  2. Abdelsamed HA, et al. Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes. Nat Immunol. 2020;21(5):578–587.
    View this article via: CrossRef PubMed Google Scholar
  3. Gearty SV, et al. An autoimmune stem-like CD8 Tcell population drives type 1 diabetes. Nature. 2022;602(7895):156–161.
    View this article via: CrossRef PubMed Google Scholar
  4. Ciecko AE, et al. Self-renewing islet TCF1+ CD8 T cells undergo IL-27-controlled differentiation to become TCF1– terminal effectors during the progression of type 1 diabetes. J Immunol. 2021;207(8):1990–2004.
    View this article via: CrossRef PubMed Google Scholar
  5. Collier JL, et al. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol. 2021;22(7):809–819.
    View this article via: CrossRef PubMed Google Scholar
  6. Gebhardt T, et al. Stem-like exhausted and memory CD8+ T cells in cancer. Nat Rev Cancer. 2023;23(11):780–798.
    View this article via: CrossRef PubMed Google Scholar
  7. Erlich HA, et al. Evidence for association of the TCF7 locus with type I diabetes. Genes Immun. 2009;10 Suppl 1(suppl 1):S54–S59.
    View this article via: CrossRef PubMed Google Scholar
  8. Noble JA, et al. A polymorphism in the TCF7 gene, C883A, is associated with type 1 diabetes. Diabetes. 2003;52(6):1579–1582.
    View this article via: CrossRef PubMed Google Scholar
  9. Zehn D, et al. ‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses. Nat Immunol. 2022;23(6):836–847.
    View this article via: CrossRef PubMed Google Scholar
  10. Warshauer JT, et al. A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance. J Exp Med. 2021;218(8):e20210759.
    View this article via: CrossRef PubMed Google Scholar
  11. Sun Q, et al. STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection. J Exp Med. 2023;220(4):e20220686.
    View this article via: CrossRef PubMed Google Scholar
  12. Woods J, et al. Cutting edge: systemic autoimmunity in murine STAT3 gain-of-function syndrome is characterized by effector T cell expansion in the absence of overt regulatory T cell dysfunction. J Immunol. 2022;209(6):1033–1038.
    View this article via: CrossRef PubMed Google Scholar
  13. Cucca F, et al. A male-female bias in type 1 diabetes and linkage to chromosome Xp in MHC HLA-DR3-positive patients. Nat Genet. 1998;19(3):301–302.
    View this article via: CrossRef PubMed Google Scholar
  14. Bosselut R. Pleiotropic Functions of H3K27Me3 Demethylases in Immune Cell Differentiation. Trends Immunol. 2016;37(2):102–113.
    View this article via: CrossRef PubMed Google Scholar
  15. Shpargel KB, et al. UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. PLoS Genet. 2012;8(9):e1002964.
    View this article via: CrossRef PubMed Google Scholar
  16. Mitchell JE, et al. UTX promotes CD8+ T cell-mediated antiviral defenses but reduces T cell durability. Cell Rep. 2021;35(2):108966.
    View this article via: CrossRef PubMed Google Scholar
  17. Noda H, et al. The histone demethylase Utx controls CD8+ T-cell-dependent antitumor immunity via epigenetic regulation of the effector function. Cancer Sci. 2023;114(7):2787–2797.
    View this article via: CrossRef PubMed Google Scholar
  18. Cook KD, et al. T follicular helper cell-dependent clearance of a persistent virus infection requires T cell expression of the histone demethylase UTX. Immunity. 2015;43(4):703–714.
    View this article via: CrossRef PubMed Google Scholar
  19. Aljobaily N, et al. Autoimmune CD4+ T cells fine-tune TCF1 expression to maintain function and survive persistent antigen exposure during diabetes. Immunity. 2024;57(11):2583–2596.
    View this article via: CrossRef PubMed Google Scholar
  20. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–485.
    View this article via: CrossRef PubMed Google Scholar
  21. Coppieters KT, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209(1):51–60.
    View this article via: CrossRef PubMed Google Scholar
  22. Gu M, et al. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol. 2021;22(2):193–204.
    View this article via: CrossRef PubMed Google Scholar
  23. Lieberman SM, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A. 2003;100(14):8384–8388.
    View this article via: CrossRef PubMed Google Scholar
  24. Verdaguer J, et al. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med. 1997;186(10):1663–1676.
    View this article via: CrossRef PubMed Google Scholar
  25. Henning AN, et al. Epigenetic control of CD8+ T cell differentiation. Nat Rev Immunol. 2018;18(5):340–356.
    View this article via: CrossRef PubMed Google Scholar
  26. Van der Meulen J, et al. The H3K27me3 demethylase UTX in normal development and disease. Epigenetics. 2014;9(5):658–668.
    View this article via: CrossRef PubMed Google Scholar
  27. Yao C, et al. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. Nat Immunol. 2021;22(3):370–380.
    View this article via: CrossRef PubMed Google Scholar
  28. Chen Z, et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity. 2019;51(5):840–855.
    View this article via: CrossRef PubMed Google Scholar
  29. Thomas HE, et al. The role of perforin and granzymes in diabetes. Cell Death Differ. 2010;17(4):577–585.
    View this article via: CrossRef PubMed Google Scholar
  30. Uniyal S, et al. Leukocytes utilize both alpha4 and alpha5 integrins for intraislet infiltration in non-obese diabetic mice. J Autoimmun. 1999;12(3):167–176.
    View this article via: CrossRef PubMed Google Scholar
  31. Barrie ES, et al. Role of ITGAE in the development of autoimmune diabetes in non-obese diabetic mice. J Endocrinol. 2015;224(3):235–243.
    View this article via: CrossRef PubMed Google Scholar
  32. Carrero JA, et al. Type I and II interferon receptors differentially regulate type 1 diabetes susceptibility in male versus female NOD mice. Diabetes. 2018;67(9):1830–1835.
    View this article via: CrossRef PubMed Google Scholar
  33. Kim CH, et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest. 2001;107(5):595–601.
    View this article via: JCI CrossRef PubMed Google Scholar
  34. Zhu L, et al. Dapl1 controls NFATc2 activation to regulate CD8+ T cell exhaustion and responses in chronic infection and cancer. Nat Cell Biol. 2022;24(7):1165–1176.
    View this article via: CrossRef PubMed Google Scholar
  35. Renoux F, et al. The AP1 transcription factor Fosl2 promotes systemic autoimmunity and inflammation by repressing Treg development. Cell Rep. 2020;31(13):107826.
    View this article via: CrossRef PubMed Google Scholar
  36. Haeryfar SMM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker. J Immunol. 2004;173(6):3581–3588.
    View this article via: CrossRef PubMed Google Scholar
  37. Tai XG, et al. A role for CD9 molecules in T cell activation. J Exp Med. 1996;184(2):753–758.
    View this article via: CrossRef PubMed Google Scholar
  38. Gattinoni L, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808–813.
    View this article via: CrossRef PubMed Google Scholar
  39. Kaya-Okur HS, et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019;10(1):1930.
    View this article via: CrossRef PubMed Google Scholar
  40. Miller SA, et al. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol Cell. 2010;40(4):594–605.
    View this article via: CrossRef PubMed Google Scholar
  41. Keenan AB, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47(w1):W212–W224.
    View this article via: CrossRef PubMed Google Scholar
  42. Galletti G, et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. Nat Immunol. 2020;21(12):1552–1562.
    View this article via: CrossRef PubMed Google Scholar
  43. Gattinoni L, et al. T memory stem cells in health and disease. Nat Med. 2017;23(1):18–27.
    View this article via: CrossRef PubMed Google Scholar
  44. Arffman M, et al. Long-term and recent trends in survival and life expectancy for people with type 1 diabetes in Finland. Diabetes Res Clin Pract. 2023;198:110580.
    View this article via: CrossRef PubMed Google Scholar
  45. Johnson MB, et al. A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes. Diabetologia. 2018;61(4):862–869.
    View this article via: CrossRef PubMed Google Scholar
  46. Fabbri M, et al. Type 1 diabetes in STAT protein family mutations: regulating the Th17/Treg equilibrium and beyond. Diabetes. 2019;68(2):258–265.
    View this article via: CrossRef PubMed Google Scholar
  47. Harker JA, et al. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science. 2011;334(6057):825–829.
    View this article via: CrossRef PubMed Google Scholar
  48. The Jackson Laboratory. Strain #029264. https://www.jax.org/strain/029264 Accessed January 2, 2026.
  49. Eto D, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS One. 2011;6(3):e17739.
    View this article via: CrossRef PubMed Google Scholar
  50. Hasham A, Tomer Y. The recent rise in the frequency of type 1 diabetes: who pulled the trigger? J Autoimmun. 2011;37(1):1–2.
    View this article via: CrossRef PubMed Google Scholar
  51. Richardson B. Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol. 2007;3(9):521–527.
    View this article via: CrossRef PubMed Google Scholar
  52. Cheng Y, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.
    View this article via: CrossRef PubMed Google Scholar
  53. Shpargel KB, et al. KDM6 demethylase independent loss of histone H3 lysine 27 trimethylation during early embryonic development. PLoS Genet. 2014;10(8):e1004507.
    View this article via: CrossRef PubMed Google Scholar
  54. Shpargel KB, et al. UTX-guided neural crest function underlies craniofacial features of Kabuki syndrome. Proc Natl Acad Sci U S A. 2017;114(43):E9046–E9055.
    View this article via: CrossRef PubMed Google Scholar
  55. Wen Z, Darnell JE Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997;25(11):2062–2067.
    View this article via: CrossRef PubMed Google Scholar
  56. Agger K, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449(7163):731–734.
    View this article via: CrossRef PubMed Google Scholar
  57. Corces MR, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017;14(10):959–962.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (December 16, 2025): In-Press Preview
  • Version 2 (February 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Introduction
  • Results
  • Discussion
  • Methods
  • Author contributions
  • Funding support
  • Supplemental material
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts